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Background. The human treponematoses are important causes of disease. Mother-to-child transmission of syphilis remains a
major cause of stillbirth and neonatal death. There are also almost 100 000 cases of endemic treponemal disease reported annually,
predominantly yaws. Rapid diagnostic tests (RDTs) would improve access to screening for these diseases. Most RDTs cannot dis-
tinguish current and previous infection. The Dual Path Platform (DPP) Syphilis Screen & Conﬁrm test includes both a treponemal
(T1) and nontreponemal (T2) component and may improve the accuracy of diagnosis.
Methods. We conducted a metaanalysis of published and unpublished evaluations of the DPP-RDT for the diagnosis of syphilis
and yaws. We calculated the sensitivity, speciﬁcity, and overall agreement of the test compared with reference laboratory tests.
Results. Nine evaluations, including 7267 tests, were included. Sensitivity was higher in patients with higher titer rapid plasma
reagin (≥1:16) for both the T1 (98.2% vs 90.1%, P < .0001) and the T2 component (98.2% vs 80.6%, P < .0001). Overall agreement
between the DPP test and reference serology was 85.2% (84.4%–86.1%). Agreement was highest for high-titer active infection and
lowest for past infection.
Conclusions. The RDT has good sensitivity and speciﬁcity of the treponemal and nontreponemal components both in cases of
suspected syphilis and yaws, although the sensitivity is decreased at lower antibody titers.
Keywords. syphilis; yaws; sexually transmitted infections; point-of-care test; metaanalysis.
The human treponematoses comprise venereal syphilis and the
endemic treponematoses yaws, bejel, and pinta. Syphilis, caused
by Treponema pallidum sp. pallidum, remains an important
cause of both morbidity and mortality. The prevalence of syph-
ilis is known to be particularly high among women attending
ante-natal clinics in sub-Saharan Africa [1], and mother-to-
child transmission of syphilis remains a major cause of stillbirth
and neonatal death worldwide. It has been estimated that mother-
to-child transmission of syphilis results in as many as 300 000
stillbirths and neonatal deaths each year in Africa alone [2].
These adverse pregnancy outcomes are entirely preventable
through syphilis screening and appropriate treatment.
Yaws is an endemic treponemal infection caused by T. pallid-
um sp. Pertenue [3]. Although closely related to T. pallidum sp.
pallidum, yaws is not sexually transmitted and predominantly
affects children living in poor, rural humid communities in
the tropics. Untreated yaws progresses to destructive lesions
of the bones and soft tissues. Between 2008 and 2012 there
were 300 000 cases of yaws reported to the World Health Orga-
nization (WHO). In 2012 the WHO launched a global effort to
eradicate the disease by 2020 [4], and the development of a
rapid diagnostic test (RDT) for yaws has been identiﬁed as a
priority for the eradication program. As yaws is serologically in-
distinguishable from syphilis [5], tests developed for syphilis
may also be of value in the diagnosis of yaws.
Diagnosis of treponemal infections is based on serological tests
that are classiﬁed as treponemal speciﬁc, such as the T. pallidum
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particle agglutination assay (TPPA), T. pallidum hemagglutina-
tion assay (TPHA), enzyme-linked immunosorbent assay (ELISA),
enzyme immunoassay (EIA), and ﬂuorescent treponemal anti-
body test, or nontreponemal, such as the venereal disease
research laboratory or the rapid plasma reagin (RPR) assay.
Treponemal tests are highly speciﬁc but frequently remain pos-
itive for life following infection, regardless of treatment or nat-
ural clearance. Nontreponemal tests are less speciﬁc but reﬂect
active disease more accurately, although positive nontrepone-
mal results may also be seen in serofast patients. Diagnosis of
treponemal infections is generally based on a combination of
both types of test as well as clinical ﬁndings and history.
RDTs for treponemal infections are a relatively recent develop-
ment; they allow wider access to diagnostic testing, particularly
for communities where routine laboratory facilities are not avail-
able. RDTs facilitate improved screening, diagnosis, and treat-
ment of syphilis in women presenting to antenatal clinics in
low-resource settings [6] and reduce the morbidity and mortality
associated with mother-to-child transmission of syphilis. For
yaws, a RDT would be of value due to the low positive predictive
value of clinical diagnosis alone [7, 8].Validation and roll-out of a
RDT would lead to improved epidemiological data on yaws
worldwide, which is a priority in facilitating eradication [4, 9].
A major limitation to most treponemal RDTs is that they are
based on detection of treponemal-speciﬁc antibodies and there-
fore cannot distinguish between current and past infection. Re-
sulting false positives lead to overtreatment of syphilis, as well
as problems in interpreting epidemiological data for both syphilis
and yaws. The Dual Path Platform (DPP-RDT) Syphilis Screen &
Conﬁrm test kit (Chembio, Medford, New York) is the ﬁrst com-
mercial RDT to give both a “treponemal” result and a “nontrepo-
nemal” result [10]. Therefore, it can assist in distinguishing
between current and past infection, which may make it a more
useful test in clinical practice. The kit is a lateral ﬂow assay that
detects both immunoglobulin (Ig)M and IgG antibodies against a
recombinant T. pallidum antigen and a nontreponemal antigen.
Several recent publications have reported on the performance of
this assay, noting good test performance; however, variations
have been noted in the sensitivity and speciﬁcity of the nontrepo-
nemal component of the test in particular. To provide more ac-
curate estimates of performance, we conducted an individual
patient-level metaanalysis on the performance of the DPP-RDT
for the diagnosis of both syphilis and yaws.
METHODS
For this review and metaanalysis we used the Preferred Reporting
Items for Systematic Reviews and Meta Analyses guidelines [11].
Search Strategy
We searched PubMed from 1 January 1960 to 1 August 2015
using the terms “RDT” OR “point of care test” AND “syphilis”
OR “yaws” (and variations). We searched reference lists of
identiﬁed articles and contacted individuals and research
groups known to have undertaken unpublished evaluation stud-
ies to identify other relevant datasets.
Inclusion Criteria
An article was included if it evaluated the sensitivity and specif-
icity of the Chembio Syphilis Screen & Conﬁrm Rapid Diagnostic
Test to detect syphilis or yaws. Laboratory, clinic, and ﬁeld-based
studies that sampled a consecutive series of patients or randomly
selected series of patients were eligible. Non-English language
publications were eligible for inclusion.
Exclusion Criteria
Articles were excluded if they did not contain primary data (eg,
editorials, reviews, and commentaries) or referred to conference
proceedings and were not accompanied by a full description of
the research.
Data Extraction and Management
The ﬁrst author screened all titles and abstracts, and the full text
was obtained for any potentially relevant articles. Full-text arti-
cles were reviewed to determine whether they met the inclusion
criteria; where this was uncertain, articles were reviewed by a
coauthor and disagreements were resolved by discussion. Data
were initially extracted by the ﬁrst author and double-checked
by the coauthors.
For each study we extracted data on the sample type used for
the DPP-RDT and the reference treponemal and nontreponemal
assay used. For each individual patient we recorded data on the
presence and stage of clinical disease, the result of the reference
treponemal and nontreponemal assays, and the result of the
DPP-RDT.
Sample types were classiﬁed as serum, plasma, whole blood,
or ﬁnger-prick. RDT results are dichotomous; reference RPR re-
sults were deemed positive at a titer ≥1:1; an RPR titer ≥1:16
was considered a high-titer RPR.
Statistical Analyses
We estimated the sensitivity and speciﬁcity of the DPP-RDT
by comparing the performance of the DPP treponemal result
(T1 component) to reference treponemal serology and by compar-
ing the performance of the DPP non treponemal result (T2 com-
ponent) to reference nontreponemal serology. Exact conﬁdence
intervals were calculated for each of these estimates using the bino-
mial distribution. The inverse variance was used to weight each
study in the metaanalysis. We calculated the I2 statistic to quantify
study variability, and sensitivities and speciﬁcities were compared
between prespeciﬁed subgroups including the RPR titer, disease,
sample type, and clinical disease stage. We conducted multivari-
able logistic regression to assess test variables including disease,
RPR titer, sample type, and reference treponemal test that were sig-
niﬁcantly associated with test performance.
We assessed the overall performance of the DPP-RDT in de-
tecting categories of infection. We classiﬁed the outcome of
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reference serology as active infection (treponemal and nontre-
ponemal test positive), past infection (treponemal test positive
and nontreponemal test negative), and no history of infection
(both tests negative). We classiﬁed the outcome of the DPP-
RDT correspondingly, as deﬁning active infection (both ele-
ments positive), past infection (only the treponemal element
positive), and no previous infection (both negative). We calcu-
lated the overall agreement between the outcome of the DPP-
RDT and the reference serology. All analyses were conducted
using Stata 13.1 (StataCorp, College Station, Texas).
The ethics committee of the London School of Hygiene &
Tropical Medicine approved the study (ref. 8908).
RESULTS
A total of 192 studies met the search criteria, and 10 articles met
the inclusion criteria [10, 12–18]. Of these, 2 articles reported
data on the same set of patients; 1 article evaluated the trepone-
mal component of 4 RDTs including the DPP-RDT [18], the
second study evaluated both the treponemal and nontrepone-
mal component of the DPP-RDT and was included in this anal-
ysis [13].Two unpublished studies were identiﬁed by contacting
groups known to have undertaken evaluations of the DPP-RDT
(Figure 1).
Overall, individual-level data from 9 studies involving 7267
test results were included in the metaanalysis. In all included
studies the individual conducting the RDT was reported to be
blinded to the results of the reference serological tests. The
countries and characteristics of the included studies are shown
in Table 1. In 1 study [10] individual-level data were only
available for 61.8% of the full dataset. The performance of the
DPP test did not differ between the full dataset and the individ-
ual-level data that were available (data not shown).
Of patients included in the study, 5656 (77.8%) underwent
treponemal testing for suspected syphilis and 1611 for suspect-
ed yaws. Individual-level clinical data on the presence or ab-
sence of disease status were available for 2636 patients
(36.3%). Of patients for whom clinical data were available,
1417 (53.8%) had clinical evidence of either active syphilis or
active yaws at the time of testing and 1219 (46.2%) had no clin-
ical evidence of active disease. The reference treponemal test
was positive in 4075 individuals (56.1%) and the reference non-
treponemal test was positive in 3112 (42.8%).
There was signiﬁcant heterogeneity across the studies in the
sensitivity of both the treponemal (I2 95.70%, P < .01) and non-
treponemal components (I2 96.70%, P < .01) (Figure 2). When
the results were restricted to high-titer samples, the heterogene-
ity was no longer statistically signiﬁcant for either treponemal
(I2 26.13%, P = .21) or nontreponemal (I2 26.13%, P = .79)
components (Supplementary Figure 1). There was also hetero-
geneity in the speciﬁcity of the treponemal component (I2
78.98%, P < .01) and the nontreponemal component (I2
97.59%, P < .01; Figure 3). As there was signiﬁcant heterogeneity
between studies, an overall pooled summary estimate of the sen-
sitivity and speciﬁcity of the RDT across the full dataset is not
reported. Sensitivity was higher for specimens from patients
with a high-titer RPR (≥1:16) (n = 1351) compared with spec-
imens with a lower RPR titer (<1:16) for both the treponemal
component (98.2% vs 90.1%, P < .0001) and the nontreponemal
Figure 1. Search results. Abbreviations: DPP, Dual Path Platform; RDT, rapid diagnostic test.
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component (98.2% vs 80.6%, P < .0001; Table 2). If all RPR-
positive samples are considered positive, the speciﬁcity of the
treponemal component was 98.0% and the speciﬁcity of the
nontreponemal component was 89.4%. If only samples with a
high-titer RPR (≥1:16) are considered positive, the speciﬁcity
of the treponemal component was 91.2% (Table 2).
The sensitivities of both test components were higher in pa-
tients with syphilis than in patients with yaws at low titers but
not at high titers. For high-titer specimens the sensitivity of the
treponemal component was 98.4% for syphilis and 97.6% for
yaws, and the sensitivity of the nontreponemal components
was 98.7% for syphilis and 96.6%for yaws. For low-titer speci-
mens the sensitivity of the treponemal component was 93.1%
for syphilis compared with 73.5% for yaws and the sensitivity
of the nontreponemal component was 85.0% for syphilis com-
pared with 59.1% yaws (P < .0001 in both cases). The speciﬁcity
of the treponemal component was slightly higher in patients
tested for syphilis compared with those tested for yaws for
low-titer specimens, while the converse was true for the nontre-
ponemal component (Table 3).
There were only minor differences in the performance of the
test based on the specimen type used (Supplementary Table 1).
The sensitivity and speciﬁcity of the treponemal component
varied depending on the reference treponemal assay used (Sup-
plementary Table 2). Compared with use of TPPA as the refer-
ence treponemal test, the sensitivity of the treponemal component
was lower when the reference test was ELISA (P < .001) and the
speciﬁcity was lower when TPHA was taken as the reference
standard. The sensitivity of both the treponemal and nontrepo-
nemal components was higher in individuals with evidence of
clinical disease than in asymptomatic cases (Supplementary
Table 3).
In multivariable logistic regression a higher RPR titer was sig-
niﬁcantly associated with an increased sensitivity of both the
Table 1. Study Characteristics




Nontreponemal Test Sample Type Sample Size Year of Publication
Ayove [16] Papua New Guinea Yaws TPHA RPR Finger-prick 199 2014
Plasma 504
Aziz Ghana Yaws TPPA RPR Finger-prick 255 Unpublished data
Castro [10] United States Syphilis TPPA RPR Serum 1168a 2010
R Castro [12] Portugal Syphilis TPHA RPR Serum 248 2014
Causer [13] Australia Syphilis ELISA/EIA RPR Serum 1005 2015
Guinard [17] France Syphilis ELISA/EIA RPR Serum 100 2013
Marks [15] Solomon Islands Yaws TPPA RPR Serum 415 2014
Taleo Vanuatu Yaws TPPA RPR Finger-prick 238 Unpublished data
Yin [14] China Syphilis TPPA TRUST Plasma 1323 2013
Whole blood 1324
Finger-prick 488
Abbreviations: EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; RPR, rapid plasma reagin; TPHA, Treponema pallidum hemagglutination assay; TPPA, Treponema
pallidum particle agglutination assay; TRUST, toluidine red unheated serum test.
a The published study size was 1889; however, individual-level data was only available for 1168 tests.
Figure 2. Forest plot of the sensitivity of the T1 (treponemal) and T2 (non-treponemal) components in comparison to reference treponemal and nontreponemal assays.
Abbreviation: CI, confidence interval.
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treponemal and the nontreponemal components (P < .001) after
controlling for other variables. After controlling for other vari-
ables, the sensitivity was lower for both test components in indi-
viduals being tested for yaws than in those tested for syphilis and
when the test was performed on serum (P < .001 in both cases).
After controlling for other variables, the speciﬁcity of the trepone-
mal component was higher when the reference standard was ei-
ther TPPA or TPHA compared with EIA or ELISA (P < .0001 in
both cases). The speciﬁcity of the nontreponemal component
was signiﬁcantly associated with the RPR titer after controlling
for other variables (P < .023).
Overall agreement between the DPP test and reference serol-
ogy was 85.2% (84.4%–86.1%). Agreement was highest for high-
titer active infection and lowest for past infection (Table 4). The
lack of agreement in this group was due to misclassiﬁcation of
both treponemal components and nontreponemal components
(data not shown).
DISCUSSION
In this metaanalysis we combined data collected from more than
7200 patients to evaluate the performance of the combined trep-
onemal–nontreponemal RDT for the diagnosis of syphilis and
yaws. The use of individual patient data from a large number
of samples allowed us to explore which factors are indepen-
dently associated with test performance. We found that the DPP
Syphilis Screen & Conﬁrm RDT has good sensitivity and specif-
icity compared with reference serology in cases of both suspected
syphilis and yaws. As previously reported in one study, the sen-
sitivity of the nontreponemal component of the RDT is related to
the patient’s RPR titer [15],with signiﬁcantly higher sensitivity of
the DPP kit for high-titer RPRs. We demonstrated that the sen-
sitivity of the treponemal component is also related to the RPR
titer. This ﬁnding was true even after controlling for other rele-
vant variables such as the sample type, disease, and reference
test used. As a result, the DPP-RDT showed excellent overall sen-
sitivity for high-titer infections (RPR ≥1:16; 97.5%) but lower
sensitivity for low-titer active infections (81.0%). Although
treponemal tests are commonly reported as either positive or
negative, quantitative testing is possible and titers to certain trep-
onemal antigens decline following treatment [19]. This, it is likely
that these ﬁndings reﬂect an overall reduced sensitivity of the
RDT at lower antibody titers. As a result, some low-titer positive
patients may be missed when the DPP-RDT is used. As the DPP-
RDT is designed to be used as a point-of-care test, the lower sen-
sitivity noted when testing serum samples may be of less clinical
relevance. However, clinicians should be aware of this when con-
sidering how to roll out rapid diagnostic testing.
Improved screening of women attending antenatal care for
syphilis is a priority intervention to reduce the mortality and
morbidity associated with mother-to-child transmission of
Figure 3. Forest plot of specificity of the T1 (treponemal) and T2 (non-treponemal) components in comparison to reference treponemal and nontreponemal assays. Abbre-
viation: CI, confidence interval.
Table 2. Overall Sensitivity and Specificity of the Dual Path Platform Rapid Diagnostic Test by Rapid Plasma Reagin Titer
RPR Titer n
Reference Test
Positive DPP Positive Sensitivity (95% CI)
Reference Test
Negative DPP Negative Specificity (95% CI)
RPR <1:16
Treponemal test 5916 2736 2464 90.1% (88.9–91.2) 3180 3115 98.0% (97.4–98.4)
Nontreponemal test 5916 1761 1419 80.6% (78.7–82.4) 4155 3714 89.4% (88.4–90.3
RPR ≥1:16
Treponemal test 1351 1339 1315 98.2% (97.3–98.8) 12 11 91.2% (61.5–99.8)
Nontreponemal test 1351 1351 1327 98.2% (97.4–98.9)
Abbreviations: CI, confidence interval; DPP, Dual Path Platform; RPR, rapid plasma reagin.
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syphilis. Most adverse pregnancy outcomes due to syphilis are
seen in mothers with an RPR titer ≥1:8 [20], and our ﬁndings
conﬁrm that the DPP-RDT has a high sensitivity in this group
(97.6%). Adoption of the DPP assay as the basis for treatment
decision would therefore be likely to detect a high proportion of
active infections. Conversely, it would reduce the number of
women having unnecessary treatment, as around half of those
with past treated infection would show up as negative on the test
compared with positive on a standard treponemal-only RDT.
This study was not designed to assess the cost-effectiveness of
a combined treponemal and nontreponemal RDT, but other
studies have shown that this is highly dependent on both the
prevalence of disease and the cost of the RDT [21]. A number
of RDTs used for antenatal settings now combine a treponemal
test with a human immunodeﬁciency virus ( HIV) test [22].
Any decision regarding the correct RDT selection and testing
strategy is likely to vary between countries, depending on the
prevalence of syphilis, yaws, and HIV and the cost and availabil-
ity of the RDTs.
Clinical diagnosis of yaws alone does not have a high predic-
tive value, and the addition of a RDT would be a signiﬁcant
advantage. In this metaanalysis, the DPP-RDT performed better
in patients with suspected syphilis than in those with suspected
yaws. This ﬁnding was explained predominantly by the lower
sensitivity in yaws patients with low titers. Although lower titers
are often found in patients with yaws compared with those with
syphilis [23], it is unclear why the test performance should be
worse in patients with yaws when controlling for antibody
titer. These ﬁndings suggest that the DPP-RDT may be adequate
in pre-mass treatment campaigns when there are many active
cases with high-titer disease but that, as the number of active
cases declines, it may be necessary to use a different testing strat-
egy, either repeated testing or adoption of an alternative test with
a higher sensitivity for low-titer disease.
A limitation of our study was that the full individual clinical
dataset was not available for 1 study [10]. The missing data rep-
resent less than 10% of the total set included in this study, and
the reported results from the full dataset do not differ signiﬁ-
cantly from the subset used in this metaanalysis. Consequently,
it seems unlikely that the missing data would substantially alter
our ﬁndings. All data analyzed were collected as part of research
studies and it is recognized that test performance may not be as
Table 4. Agreement of the Dual Path Platform Test Kit Classification Relative to Reference Serology
Serological Classification Reference Test Classification Dual Path Platform Test Classification Agreement (95% Confidence Interval)
Active 3021 2668 88.3% (87.1–89.4)
Active (high titer ≥1:16) 1339 1306 97.5% (96.6–98.3)
Active (low titer <1:16) 1682 1362 81.0% (79.1–82.8)
Past infection 1054 570 54.1% (51.1–57.1)
No infection 3101 2938 94.7% (93.9–95.6)
False-positive rapid plasma reagina 91 19 20.9% (13.1–30.7)
a A rapid plasma reagin (RPR) was considered a false positive if the treponemal test was negative. This may be overly conservative as the RPRmay become positive before the treponemal test.
This definition would not affect our estimate of the agreement between the Dual Path Platform test and the reference test in this scenario.









Negative Specificity (95% CI)
Syphilis
RPR <1:16
Treponemal test 4600 2310 2151 93.1% (92.0–94.1) 2290 2256 98.5% (97.9–99.0)
Nontreponemal test 4600 1460 1241 85.0% (83.1–86.8) 3140 2750 87.6% (86.4–88.7)
RPR ≥1:16
Treponemal test 1056 1049 1032 98.4% (97.4–99.1) 7 7 100% (59–100)
Nontreponemal test 1056 1056 1042 98.7% (97.8–99.3)
Yaws
RPR <1:16
Treponemal test 1316 426 313 73.5% (69.0–77.6) 890 859 96.5% (95.1–97.6)
Nontreponemal test 1316 301 178 59.1% (53.3–64.7) 1015 964 95.0% (93.4–96.2)
RPR ≥1:16
Treponemal test 295 290 283 97.6% (95.1–99.0) 5 4 80.0% (28.4–99.5)
Nontreponemal test 295 295 285 96.6% (93.8–98.4)
Abbreviations: CI, confidence interval; DPP, Dual Path Platform; RPR, rapid plasma reagin.
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good in a real-world setting in the hands of the end users
(healthcare workers) and that the use of test results may be in-
ﬂuenced by factors other than simply the result [24]. Training
and support for healthcare workers has been shown to signiﬁ-
cantly improve use of RDTs in other areas [25] and should be a
key component of the roll-out of RDTs for syphilis and yaws.
This metaanalysis demonstrates that the DPP-RDT has high
sensitivity and speciﬁcity for both treponemal and nontrepone-
mal antibodies. Our analysis includes a large number of patients
from many countries who were enrolled in studies and tested
for syphilis or yaws. Our large sample size allows us to provide
the most accurate estimates published to date of the test perfor-
mance across a range of subgroups. The major limitation of the
DPP-RDT is its reduced sensitivity for low-titer disease. As RPR
titers tend to be higher in patients with syphilis than in patients
with yaws, this reduced sensitivity is likely to be a greater prob-
lem when using the test as part of yaws eradication efforts, es-
pecially as a high-sensitivity assay will be needed to ensure all
cases are detected to conﬁrm the ﬁnal eradication status of
the infection. Combined treponemal–nontreponemal assays
offer a number of advantages over treponemal only RDTs.
Our data provide evidence to support the decision to use the
DPP-RDT as one such assay.
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